Abstract

<p>PDF file - 930KB, The supplementary file includes: Figure S1. Effects of dasatinib on uterine and ovarian cancer cells. Figure S2. Effects of dasatinib based on PTEN status. Figure S3. RPPA analysis of expression levels of 176 proteins in uterine cancer cells treated with dasatinib, paclitaxel, or both. Figure S4. Effect of dasatinib on selected proteins in uterine cancer cell lines. Figure S5. Effect of dasatinib on uterine cancer cell lines with or without EphA2 silencing. Figure S6. In vivo effects of dasatinib and paclitaxel on mouse models of uterine carcinoma. Table S1. Candidate predictive markers for response to dasatinib in uterine cancer. Table S2. Basal expression levels of putative dasatinib response markers in human normal uterine and uterine cancer samples. Table S3. Proteins that differed among controls and treated SPEC-2 cells Table S4. Mean fold change of proteins in SPEC-2 cell line Table S5. Proteins that differed among controls and treated SKUT-2 cells Table S6. Mean fold change of proteins in SKUT-2 cell line Table S7. Proteins that differed among controls and treated HEC1-A cells Table S8. Mean fold change of proteins in HEC1-A cell line Table S9. Proteins that differed among controls and treated Ishikawa cells Table S10. Mean fold change of proteins in Ishikawa cell line.</p>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.